Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/targeted-therapies-for-her2-breast-cancer-a-view-of-the-landscape-cjsuzVgaUL
References (48)
-
E. Friedländer, Mark Barok, J. Szöllősi, G. Vereb (2008)
ErbB-directed immunotherapy: antibodies in current practice and promising new agents.Immunology letters, 116 2
-
C. Ritter, Marianela Pérez-Torres, C. Rinehart, M. Guix, T. Dugger, J. Engelman, C. Arteaga (2007)
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor NetworkClinical Cancer Research, 13
-
DJ Slamon, B Leyland-Jones, S Shak (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344
-
I. Krop, M. Beeram, S. Modi, Suzanne Jones, S. Holden, Wei Yu, S. Girish, J. Tibbitts, J. Yi, M. Sliwkowski, Frederic Jacobson, S. Lutzker, H. Burris (2010)
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 16
-
H. Burstein, Yan Sun, L. Dirix, Zefei Jiang, R. Paridaens, A. Tan, A. Awada, A. Ranade, S. Jiao, G. Schwartz, R. Abbas, C. Powell, K. Turnbull, J. Vermette, C. Zacharchuk, R. Badwe (2010)
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 8
-
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press (2023)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 41
-
Y. Izumi, Lei Xu, E. Tomaso, D. Fukumura, R. Jain (2002)
Tumour biology: Herceptin acts as an anti-angiogenic cocktailNature, 416
-
B. Moy, P. Goss (2007)
TEACH: Tykerb evaluation after chemotherapy.Clinical breast cancer, 7 6
-
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
D. Slamon, W. Eiermann, N. Robert, T. Pieńkowski, Miguel Martín, J. Rolski, A. Chan, J. Mackey, M. Liu, T. Pintér, V. Valero, C. Falkson, T. Fornander, T. Shiftan, S. Olsen, M. Buyse, T. Kiskartalyi, V. Landreau, V. Wilson, M. Press, J. Crown (2009)
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.Cancer Research, 69
-
Hyun-soo Cho, K. Mason, K. Ramyar, A. Stanley, S. Gabelli, D. Denney, D. Leahy (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 421
-
F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, M. Jacomuzzi, G. Valabrega, S. Danese, G. Vietti-Ramus, A. Durando, M. Venturini, M. Aglietta (2006)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.The oncologist, 11 4
-
R. Swaby, Kimberly Blackwell, Zefei Jiang, Y. Sun, V. Diéras, K. Zaman, C. Zacharchuk, C. Powell, R. Abbas, M. Thakuria (2009)
Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
H. Joensuu, P. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, T. Turpeenniemi‐Hujanen, S. Jyrkkiö, M. Flander, L. Helle, S. Ingalsuo, Kaisu Johansson, A. Jääskeläinen, M. Pajunen, Mervi Rauhala, J. Kaleva-Kerola, T. Salminen, M. Leinonen, I. Elomaa, J. Isola (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.The New England journal of medicine, 354 8
-
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
-
G. Peoples, J. Holmes, M. Hueman, E. Mittendorf, Asna Amin, S. Khoo, Z. Dehqanzada, J. Gurney, Michael Woll, G. Ryan, C. Storrer, D. Craig, C. Ioannides, S. Ponniah (2008)
Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 14
-
Yoichi Nagata, K. Lan, Xiaoyan Zhou, M. Tan, F. Esteva, A. Sahin, K. Klos, Ping Li, B. Monia, Nina Nguyen, G. Hortobagyi, M. Hung, Dihua Yu (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer cell, 6 2
-
G. Minckwitz, H. Eidtmann, S. Loibl, J. Blohmer, S. Costa, P. Fasching, R. Kreienberg, J. Hilfrich, B. Gerber, C. Hanusch, T. Fehm, D. Strumberg, C. Solbach, V. Nekljudova, M. Untch (2011)
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.Annals of oncology : official journal of the European Society for Medical Oncology, 22 2
-
Freddie Hamdy, Jenny Donovan, Athene, Chris Metcalfe, M. Davis, R. Martin, Bollina J., Andrew Doble, Alan Doherty, Gillatt, Gnanapragasam David, O. Hughes, Howard, A. Paul, E. Paez, P. Powell, M. Mason, J. Oxley, J. Lane, M. Davis, E. Turner, G. Young, E. Walsh, R. Bryant, P. Bollina, D. Gillatt, V. Gnanapragasam, O. Hughes, R. Kockelbergh, H. Kynaston, E. Paez, P. Powell, D. Rosario, E. Rowe, M. Mason, T. Peters, J. Oxley, N. Williams, J. Staffurth, D. Neal (2023)
The n e w e n g l a n d j o u r n a l of m e d i c i n e -
C. Baxevanis, P. Sotiropoulou, Nectaria Sotiriadou, M. Papamichail (2004)
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapyCancer Immunology, Immunotherapy, 53
-
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England journal of medicine, 355 26
-
J. Baselga, K. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortés, V. Mcnally, G. Ross, P. Fumoleau, L. Gianni (2010)
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
C. Vogel, H. Burris, S. Limentani, R. Borson, J. O’Shaughnessy, S. Vukelja, S. Agresta, B. Klencke, M. Birkner, H. Rugo (2009)
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
-
J. Baselga, J. Albanell (2001)
Mechanism of action of anti-HER2 monoclonal antibodies.Annals of oncology : official journal of the European Society for Medical Oncology, 12 Suppl 1
-
N. Lin, L. Carey, Minetta Liu, J. Younger, S. Come, M. Ewend, G. Harris, E. Bullitt, A. Abbeele, J. Henson, Xiaochun Li, R. Gelman, H. Burstein, E. Kasparian, D. Kirsch, Ann Crawford, F. Hochberg, E. Winer (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
-
M. Owens, B. Horten, M. Silva (2004)
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.Clinical breast cancer, 5 1
-
B. Kaufman, J. Mackey, M. Clemens, P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Révil, A. Jones (2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
J. Ross, E. Slodkowska, W. Symmans, L. Pusztai, P. Ravdin, G. Hortobagyi (2009)
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.The oncologist, 14 4
-
P. Kiewe, S. Hasmüller, S. Kahlert, M. Heinrigs, B. Rack, A. Marmé, A. Korfel, M. Jäger, H. Lindhofer, H. Sommer, E. Thiel, M. Untch (2006)
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast CancerClinical Cancer Research, 12
-
R. Gennari, S. Ménard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, B. Oliviero, B. Ballardini, G. Prada, A. Zambelli, Alberto Costa (2004)
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2Clinical Cancer Research, 10
-
D Slamon, W Eiermann, N Robert (2006)
BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patientsBreast Cancer Res Treat, 100
-
R. Repp, H. Ojik, T. Valerius, G. Groenewegen, G. Wieland, C. Oetzel, B. Stockmeyer, Wendy Becker, M. Eisenhut, H. Steininger, Y. Deo, G. Blijham, J. Kalden, J. Winkel, M. Gramatzki (2003)
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerBritish Journal of Cancer, 89
-
S. Lee-Hoeflich, Lisa Crocker, E. Yao, Thinh Pham, Xander Munroe, K. Hoeflich, M. Sliwkowski, H. Stern (2008)
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.Cancer research, 68 14
-
G. Minckwitz, C. Zielinski, E. Maarteense, P. Vogel, M. Schmidt, H. Eidtmann, T. Čufer, F. Jongh, M. Kaufmann, S. Loibl (2008)
Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)Journal of Clinical Oncology, 26
-
M. Cobleigh, C. Vogel, D. Tripathy, N. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, D. Slamon (1999)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
-
E. Wood, A. Truesdale, O. McDonald, D. Yuan, A. Hassell, S. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K. Alligood, D. Rusnak, T. Gilmer, L. Shewchuk (2004)
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)Cancer Research, 64
-
D. Tripathy, D. Slamon, M. Cobleigh, A. Arnold, M. Saleh, J. Mortimer, M. Murphy, S. Stewart (2004)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 6
-
J. Bendell, S. Domchek, H. Burstein, L. Harris, J. Younger, I. Kuter, C. Bunnell, M. Rue, R. Gelman, E. Winer (2003)
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 97
-
M. Narayan, J. Wilken, L. Harris, A. Baron, K. Kimbler, N. Maihle (2009)
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.Cancer research, 69 6
-
Michael Nelson, Christian Dolder (2006)
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid TumorsAnnals of Pharmacotherapy, 40
-
ER Wood, AT Truesdale, OB McDonald (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsCancer Res, 64
-
S. Hurvitz, M. Pegram, L. Lin, D. Chan, H. Allen, R. Dichmann, C. Hagenstad, John Barstis, R. Hermann, E. Hu, R. Moroose, S. Thomas, C. Vogel, N. Ryba, D. Elashoff, D. Slamon (2009)
Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.Cancer Research, 69
-
S. Johnston, J. Pippen, X. Pivot, M. Lichinitser, S. Sadeghi, V. Diéras, H. Gómez, G. Romieu, A. Manikhas, M. Kennedy, M. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein, M. Pegram (2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
-
Y. Yarden (2001)
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.European journal of cancer, 37 Suppl 4
-
S. Rabindran, C. Discafani, E. Rosfjord, M. Baxter, M. Floyd, J. Golas, W. Hallett, Bernard Johnson, R. Nilakantan, E. Overbeek, M. Reich, R. Shen, Xiaoqing Shi, H. Tsou, Yu-Fen Wang, A. Wissner (2004)
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine KinaseCancer Research, 64
-
C. Denlinger, M. Beeram, A. Tolcher, L. Goldstein, W. Slichenmyer, J. Murray, C. McDonagh, K. Andreas, V. Moyo (2010)
A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers.Journal of Clinical Oncology, 28
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-010-0037-x
- Publisher site
- See Article on Publisher Site
Abstract
Trastuzumab was first described over 25 years ago and was approved for clinical use a decade ago. Since then, marked improvement in survival in patients with breast cancer has been achieved with use of trastuzumab. There is still room for improvement however, as approximately 40% of patients with HER2-amplified breast cancer do not derive significant benefit from trastuzumab. Furthermore, in patients with advanced disease, most patients who do respond end up developing resistance and progressive recurrent disease. Significant advances have been made in the understanding of acquired resistance to trastuzumab, and a large of number of newer HER2-directed therapies have been rationally developed targeting trastuzumab-resistant disease. Small molecules targeting multiple HER family tyrosine kinases such as lapatinib and neratinib have been the most promising.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Jan 30, 2011